200 related articles for article (PubMed ID: 21459261)
1. Statin-associated rhabdomyolysis: is there a dose-response relationship?
Holbrook A; Wright M; Sung M; Ribic C; Baker S
Can J Cardiol; 2011; 27(2):146-51. PubMed ID: 21459261
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes.
Colivicchi F; Tubaro M; Santini M
Int J Cardiol; 2011 Oct; 152(1):56-60. PubMed ID: 20674999
[TBL] [Abstract][Full Text] [Related]
3. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
McAdams M; Staffa J; Dal Pan G
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
Golomb B; Evans M
Drug Saf; 2006; 29(12):1191; author reply 1191-2. PubMed ID: 17147465
[No Abstract] [Full Text] [Related]
5. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
[No Abstract] [Full Text] [Related]
6. Hypernatremia due to rhabdomyolysis in a patient on statin.
Victor SM; Gnanaraj A; Abraham G; Sankardas MA
Saudi J Kidney Dis Transpl; 2011 Sep; 22(5):1037-8. PubMed ID: 21912045
[No Abstract] [Full Text] [Related]
7. [Rhabdomyolysis associated to combined ezetimibe-statin treatment].
Piedra León M; García Unzueta MT; Otero Martínez M; Amado Señaris JA
Rev Clin Esp; 2007 Sep; 207(8):425-6. PubMed ID: 17688879
[No Abstract] [Full Text] [Related]
8. Rhabdomyolysis with atorvastatin and fusidic acid.
O'Mahony C; Campbell VL; Al-Khayatt MS; Brull DJ
Postgrad Med J; 2008 Jun; 84(992):325-7. PubMed ID: 18644925
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin for stroke prevention.
Med Lett Drugs Ther; 2006 Sep; 48(1243):75-6. PubMed ID: 16977287
[No Abstract] [Full Text] [Related]
10. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
11. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
Alsheikh-Ali AA; Karas RH
Am J Cardiol; 2004 Jun; 93(11):1417-8, A9. PubMed ID: 15165929
[TBL] [Abstract][Full Text] [Related]
12. Safety of high-dose atorvastatin therapy.
Waters DD
Am J Cardiol; 2005 Sep; 96(5A):69F-75F. PubMed ID: 16126026
[TBL] [Abstract][Full Text] [Related]
13. Statin adverse effects: sorting out the evidence.
Mlodinow SG; Onysko MK; Vandiver JW; Hunter ML; Mahvan TD
J Fam Pract; 2014 Sep; 63(9):497-506. PubMed ID: 25353029
[No Abstract] [Full Text] [Related]
14. Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin.
Magee CN; Medani SA; Leavey SF; Conlon PJ; Clarkson MR
Am J Kidney Dis; 2010 Nov; 56(5):e11-5. PubMed ID: 20888103
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J
Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019
[TBL] [Abstract][Full Text] [Related]
16. [Rhabdomyolysis following the coprescription of atorvastatin and fusidic acid].
Gabignon C; Zeller V; Le Guyader N; Desplaces N; Lidove O; Ziza JM
Rev Med Interne; 2013 Jan; 34(1):39-41. PubMed ID: 23102978
[TBL] [Abstract][Full Text] [Related]
17. Intensive lipid lowering with atorvastatin in coronary disease.
Ravnskov U; Rosch PJ; Sutter MC
N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003834
[No Abstract] [Full Text] [Related]
18. Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
Bangalore S; Fayyad R; Hovingh GK; Laskey R; Vogt L; DeMicco DA; Waters DD;
Am J Cardiol; 2014 Jun; 113(12):2018-20. PubMed ID: 24793673
[TBL] [Abstract][Full Text] [Related]
19. Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
Davidson MH
Am J Cardiol; 2005 Nov; 96(9A):3K-13K; discussion 34K-35K. PubMed ID: 16291008
[TBL] [Abstract][Full Text] [Related]
20. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.
Nichols GA; Koro CE
Clin Ther; 2007 Aug; 29(8):1761-70. PubMed ID: 17919557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
